Tromsø, Norway, May 13th, 2024 - ArcticZymes Technologies (OSE: AZT) announces Nominations for new Board members and the resignation of the Chairman and a Board member.

ArcticZymes today announces changes to its governance structure. The Election committee has proposed changes to the Board to guide and strengthen the strategic and commercial development of the company.

Nomination of New Board Members

ArcticZymes is pleased to introduce three distinguished individuals nominated to join its Board of directors. These nominees bring expertise and experience in the biomanufacturing and financial sectors, enriching ArcticZymes' strategic direction, commercialization efforts, and governance practices:

  • Mrs. Sharon Brownlow: With a background in Biotech and extensive experience in the cell and gene therapy industry, Mrs. Brownlow is renowned for blending her scientific roots with entrepreneurial drive. Her proven track record includes senior commercial roles in Catapult and Cobra Biologics, where she effectively drove strategic business momentum and long-term revenue growth.
  • Mr. Petter Dragesund: Former Senior Partner at Pareto Securities, Mr. Dragesund boasts nearly three decades of experience in investment banking. Serving in various capacities at Pareto from 1992 to 2021, including Head of the Corporate Finance department from 2001 to 2014, he brings invaluable financial acumen to the Board. Since 2021, Mr. Dragesund has been an independent investor, further broadening his insights into market dynamics.
  • A third Board member, currently a Life Science Executive, will be nominated shortly. With a remarkable track record in scaling public life science companies and devising successful growth strategies, this individual possesses deep insights into the challenges and opportunities within drug development and commercialization broadly.

Resignation of Chairman and Board Member

Mrs. Marie Roskrow, Chairman of the Board, has resigned, effective immediately. During her six-year tenure, Mrs. Roskrow played a pivotal role in elevating ArcticZymes into a globally profitable player in the life science tools sector. Her leadership laid a robust foundation for long-term growth, for which the Election committee extends its sincere appreciation.

Board member Mrs. Jane Theaker has also resigned, citing personal reasons. The committee acknowledges Mrs. Theaker's valuable contributions and thanks her for her service.

New date of the Annual General Meeting (AGM) is June 26th, 2024

For practical reasons ArcticZymes has decided to move its Annual General Meeting (AGM), originally scheduled for June 5th, to June 26th, 2024. The financial calendar will be updated as well. 

-Ends-

For more information, please contact:

ArcticZymes Technologies ASA
CEO,  MIchael B. Akoh                        Tel: +46 (0) 70 262 37 15
CFO, Børge Sørvoll                              Tel: +47 952 90 187
ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the development, manufacturing and commercialization of novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

Listed on the Oslo Stock Exchange since 2005 originally under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large portfolio of patents.

For more information, please visit the website: www.arcticzymes.com

http://publish.ne.cision.com//Release/ViewReleaseHtml/D8E175BA8A94A452E0C856B0705FC7D6

https://mb.cision.com/Main/1090/3977999/2793274.pdf

(c) 2024 Cision. All rights reserved., source Press Releases - English